SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-049436
Filing Date
2024-04-29
Accepted
2024-04-29 07:05:18
Documents
12
Period of Report
2024-04-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20240429.htm   iXBRL 8-K 49985
2 EX-10.1 cgem-ex10_1.htm EX-10.1 127044
  Complete submission text file 0000950170-24-049436.txt   317806

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20240429.xsd EX-101.SCH 25882
15 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20240429_htm.xml XML 4889
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

IRS No.: 813867811 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 24886559
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)